Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 287

1.

Objective breast symmetry analysis with the breast analyzing tool (BAT): improved tool for clinical trials.

Krois W, Romar AK, Wild T, Dubsky P, Exner R, Panhofer P, Jakesz R, Gnant M, Fitzal F.

Breast Cancer Res Treat. 2017 Jul;164(2):421-427. doi: 10.1007/s10549-017-4255-z. Epub 2017 May 2.

2.

Adjuvant Bisphosphonates and Breast Cancer Survival.

Strobl S, Korkmaz B, Devyatko Y, Schuetz M, Exner R, Dubsky PC, Jakesz R, Gnant M.

Annu Rev Med. 2016;67:1-10. doi: 10.1146/annurev-med-053014-103600. Epub 2015 Aug 28. Review.

PMID:
26332000
3.

Postoperative CMF Does Not Ameliorate Poor Outcomes in Women With Residual Invasive Breast Cancer After Neoadjuvant Epirubicin/Docetaxel Chemotherapy.

Promberger R, Dubsky P, Mittlböck M, Ott J, Singer C, Seemann R, Exner R, Panhofer P, Steger G, Bergen E, Gnant M, Jakesz R, Bago-Horvath Z, Rudas M, Bartsch R.

Clin Breast Cancer. 2015 Dec;15(6):505-11. doi: 10.1016/j.clbc.2015.06.007. Epub 2015 Jun 18.

PMID:
26195436
4.

Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.

Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R, Wette V, Balic M, Haslbauer F, Melbinger E, Bjelic-Radisic V, Artner-Matuschek S, Fitzal F, Marth C, Sevelda P, Mlineritsch B, Steger GG, Manfreda D, Exner R, Egle D, Bergh J, Kainberger F, Talbot S, Warner D, Fesl C, Singer CF; Austrian Breast and Colorectal Cancer Study Group.

Lancet. 2015 Aug 1;386(9992):433-43. doi: 10.1016/S0140-6736(15)60995-3. Epub 2015 May 31.

PMID:
26040499
5.

TP53 germline mutation may affect response to anticancer treatments: analysis of an intensively treated Li-Fraumeni family.

Kappel S, Janschek E, Wolf B, Rudas M, Teleky B, Jakesz R, Kandioler D.

Breast Cancer Res Treat. 2015 Jun;151(3):671-8. doi: 10.1007/s10549-015-3424-1. Epub 2015 May 16.

PMID:
25981898
6.

Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype.

Gnant M, Sestak I, Filipits M, Dowsett M, Balic M, Lopez-Knowles E, Greil R, Dubsky P, Stoeger H, Rudas M, Jakesz R, Ferree S, Cowens JW, Nielsen T, Schaper C, Fesl C, Cuzick J.

Ann Oncol. 2015 Aug;26(8):1685-91. doi: 10.1093/annonc/mdv215. Epub 2015 May 1.

PMID:
25935792
7.

Quality of life after sympathetic surgery at the T4 ganglion for primary hyperhidrosis: clip application versus diathermic cut.

Panhofer P, Ringhofer C, Gleiss A, Jakesz R, Prager M, Bischof G, Neumayer C.

Int J Surg. 2014 Dec;12(12):1478-83. doi: 10.1016/j.ijsu.2014.11.018. Epub 2014 Nov 18.

8.

Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.

Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Knauer M, Moik M, Jakesz R, Seifert M, Taucher S, Bjelic-Radisic V, Balic M, Eidtmann H, Eiermann W, Steger G, Kwasny W, Dubsky P, Selim U, Fitzal F, Hochreiner G, Wette V, Sevelda P, Ploner F, Bartsch R, Fesl C, Greil R; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria.

Ann Oncol. 2015 Feb;26(2):313-20. doi: 10.1093/annonc/mdu544. Epub 2014 Nov 17.

PMID:
25403582
9.

The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER+, HER2- early breast cancer.

Exner R, Bago-Horvath Z, Bartsch R, Mittlboeck M, Retèl VP, Fitzal F, Rudas M, Singer C, Pfeiler G, Gnant M, Jakesz R, Dubsky P.

Br J Cancer. 2014 Aug 26;111(5):837-42. doi: 10.1038/bjc.2014.339. Epub 2014 Jul 8.

10.

The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer.

Filipits M, Nielsen TO, Rudas M, Greil R, Stöger H, Jakesz R, Bago-Horvath Z, Dietze O, Regitnig P, Gruber-Rossipal C, Müller-Holzner E, Singer CF, Mlineritsch B, Dubsky P, Bauernhofer T, Hubalek M, Knauer M, Trapl H, Fesl C, Schaper C, Ferree S, Liu S, Cowens JW, Gnant M; Austrian Breast and Colorectal Cancer Study Group.

Clin Cancer Res. 2014 Mar 1;20(5):1298-305. doi: 10.1158/1078-0432.CCR-13-1845. Epub 2014 Feb 11.

11.

Standardization of morbidity assessment in breast cancer surgery using the Clavien Dindo Classification.

Panhofer P, Ferenc V, Schütz M, Gleiss A, Dubsky P, Jakesz R, Gnant M, Fitzal F.

Int J Surg. 2014;12(4):334-9. doi: 10.1016/j.ijsu.2014.01.012. Epub 2014 Jan 31.

12.

Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24).

Steger GG, Greil R, Lang A, Rudas M, Fitzal F, Mlineritsch B, Hartmann BL, Bartsch R, Melbinger E, Hubalek M, Stoeger H, Dubsky P, Ressler S, Petzer AL, Singer CF, Muss C, Jakesz R, Gampenrieder SP, Zielinski CC, Fesl C, Gnant M; Austrian Breast and Colorectal Study Group (ABCSG).

Ann Oncol. 2014 Feb;25(2):366-71. doi: 10.1093/annonc/mdt508. Epub 2013 Dec 16.

PMID:
24347519
13.

Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone.

Gnant M, Filipits M, Greil R, Stoeger H, Rudas M, Bago-Horvath Z, Mlineritsch B, Kwasny W, Knauer M, Singer C, Jakesz R, Dubsky P, Fitzal F, Bartsch R, Steger G, Balic M, Ressler S, Cowens JW, Storhoff J, Ferree S, Schaper C, Liu S, Fesl C, Nielsen TO; Austrian Breast and Colorectal Cancer Study Group.

Ann Oncol. 2014 Feb;25(2):339-45. doi: 10.1093/annonc/mdt494. Epub 2013 Dec 16.

PMID:
24347518
14.

The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients.

Dubsky P, Brase JC, Jakesz R, Rudas M, Singer CF, Greil R, Dietze O, Luisser I, Klug E, Sedivy R, Bachner M, Mayr D, Schmidt M, Gehrmann MC, Petry C, Weber KE, Fisch K, Kronenwett R, Gnant M, Filipits M; Austrian Breast and Colorectal Cancer Study Group (ABCSG).

Br J Cancer. 2013 Dec 10;109(12):2959-64. doi: 10.1038/bjc.2013.671. Epub 2013 Oct 24.

15.

Long-term outcomes after endothoracic sympathetic block at the T4 ganglion for upper limb hyperhidrosis.

Panhofer P, Gleiss A, Eilenberg WH, Jakesz R, Bischof G, Neumayer C.

Br J Surg. 2013 Oct;100(11):1471-7. doi: 10.1002/bjs.9275.

PMID:
24037567
16.

The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial.

Gnant M, Pfeiler G, Stöger H, Mlineritsch B, Fitzal F, Balic M, Kwasny W, Seifert M, Stierer M, Dubsky P, Greil R, Steger G, Samonigg H, Fesl C, Jakesz R.

Br J Cancer. 2013 Aug 6;109(3):589-96. doi: 10.1038/bjc.2013.367. Epub 2013 Jul 18.

17.

Efficacy of tamoxifen ± aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial.

Pfeiler G, Stöger H, Dubsky P, Mlineritsch B, Singer C, Balic M, Fitzal F, Moik M, Kwasny W, Selim U, Renner K, Ploner F, Steger GG, Seifert M, Hofbauer F, Sandbichler P, Samonigg H, Jakesz R, Greil R, Fesl C, Gnant M; ABCSG.

Br J Cancer. 2013 Apr 16;108(7):1408-14. doi: 10.1038/bjc.2013.114. Epub 2013 Mar 19.

18.

Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trial.

Oakman C, Francis PA, Crown J, Quinaux E, Buyse M, De Azambuja E, Margeli Vila M, Andersson M, Nordenskjöld B, Jakesz R, Thürlimann B, Gutiérrez J, Harvey V, Punzalan L, Dell'orto P, Larsimont D, Steinberg I, Gelber RD, Piccart-Gebhart M, Viale G, Di Leo A.

Ann Oncol. 2013 May;24(5):1203-11. doi: 10.1093/annonc/mds627. Epub 2013 Jan 4.

PMID:
23293111
19.

CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8.

Goetz MP, Suman VJ, Hoskin TL, Gnant M, Filipits M, Safgren SL, Kuffel M, Jakesz R, Rudas M, Greil R, Dietze O, Lang A, Offner F, Reynolds CA, Weinshilboum RM, Ames MM, Ingle JN.

Clin Cancer Res. 2013 Jan 15;19(2):500-7. doi: 10.1158/1078-0432.CCR-12-2153. Epub 2012 Dec 4.

20.

EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer.

Dubsky P, Filipits M, Jakesz R, Rudas M, Singer CF, Greil R, Dietze O, Luisser I, Klug E, Sedivy R, Bachner M, Mayr D, Schmidt M, Gehrmann MC, Petry C, Weber KE, Kronenwett R, Brase JC, Gnant M; Austrian Breast and Colorectal Cancer Study Group (ABCSG).

Ann Oncol. 2013 Mar;24(3):640-7. doi: 10.1093/annonc/mds334. Epub 2012 Oct 3.

21.

Influence of resection extent on morbidity in surgery for squamous cell cancer at the pharyngoesophageal junction.

Panhofer P, Springer C, Izay B, Grasl M, Burian M, Schoppmann SF, Rath T, Jakesz R, Zacherl J.

Langenbecks Arch Surg. 2013 Feb;398(2):221-30. doi: 10.1007/s00423-012-0995-8. Epub 2012 Sep 2.

PMID:
22941244
22.

Podoplanin-expressing cancer-associated fibroblasts are associated with poor prognosis in invasive breast cancer.

Schoppmann SF, Berghoff A, Dinhof C, Jakesz R, Gnant M, Dubsky P, Jesch B, Heinzl H, Birner P.

Breast Cancer Res Treat. 2012 Jul;134(1):237-44. doi: 10.1007/s10549-012-1984-x. Epub 2012 Feb 17.

PMID:
22350732
23.

Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group.

Dubsky PC, Jakesz R, Mlineritsch B, Pöstlberger S, Samonigg H, Kwasny W, Tausch C, Stöger H, Haider K, Fitzal F, Singer CF, Stierer M, Sevelda P, Luschin-Ebengreuth G, Taucher S, Rudas M, Bartsch R, Steger GG, Greil R, Filipcic L, Gnant M.

J Clin Oncol. 2012 Mar 1;30(7):722-8. doi: 10.1200/JCO.2011.36.8993. Epub 2012 Jan 23.

PMID:
22271481
24.

Prognostic value of number of removed lymph nodes, number of involved lymph nodes, and lymph node ratio in 7502 breast cancer patients enrolled onto trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG).

Tausch C, Taucher S, Dubsky P, Seifert M, Reitsamer R, Kwasny W, Jakesz R, Fitzal F, Filipcic L, Fridrik M, Greil R, Gnant M.

Ann Surg Oncol. 2012 Jun;19(6):1808-17. doi: 10.1245/s10434-011-2189-y. Epub 2011 Dec 30.

PMID:
22207051
25.

Objectively measured breast symmetry has no influence on quality of life in breast cancer patients.

Exner R, Krois W, Mittlböck M, Dubsky P, Jakesz R, Gnant M, Fitzal F.

Eur J Surg Oncol. 2012 Feb;38(2):130-6. doi: 10.1016/j.ejso.2011.10.012. Epub 2011 Dec 5.

PMID:
22152943
26.

Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer.

Bago-Horvath Z, Rudas M, Dubsky P, Jakesz R, Singer CF, Kemmerling R, Greil R, Jelen A, Böhm G, Jasarevic Z, Haid A, Gruber C, Pöstlberger S, Filipits M, Gnant M; Austrian Breast and Colorectal Cancer Study Group.

Clin Cancer Res. 2011 Dec 15;17(24):7828-34. doi: 10.1158/1078-0432.CCR-11-1846. Epub 2011 Oct 13.

27.

Fine-tuning the truth.

Elder EE, Jakesz R.

World J Surg. 2011 Oct;35(10):2185-6. doi: 10.1007/s00268-011-1233-1. No abstract available.

PMID:
21850600
28.

A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.

Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF, Dietze O, Greil R, Jelen A, Sevelda P, Freibauer C, Müller V, Jänicke F, Schmidt M, Kölbl H, Rody A, Kaufmann M, Schroth W, Brauch H, Schwab M, Fritz P, Weber KE, Feder IS, Hennig G, Kronenwett R, Gehrmann M, Gnant M; EP Investigators.

Clin Cancer Res. 2011 Sep 15;17(18):6012-20. doi: 10.1158/1078-0432.CCR-11-0926. Epub 2011 Aug 1.

29.

Neoadjuvant chemotherapy increases the rate of breast conservation in lobular-type breast cancer patients.

Fitzal F, Mittlboeck M, Steger G, Bartsch R, Rudas M, Dubsky P, Riedl O, Jakesz R, Gnant M.

Ann Surg Oncol. 2012 Feb;19(2):519-26. doi: 10.1245/s10434-011-1879-9. Epub 2011 Jul 9.

PMID:
21743980
30.

Surgery for liver metastases originating from sarcoma-case series.

Zacherl M, Bernhardt GA, Zacherl J, Gruber G, Kornprat P, Bacher H, Mischinger HJ, Windhager R, Jakesz R, Grünberger T.

Langenbecks Arch Surg. 2011 Oct;396(7):1083-91. doi: 10.1007/s00423-011-0821-8. Epub 2011 Jul 8.

PMID:
21739304
31.

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.

Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Heck D, Menzel C, Jakesz R, Seifert M, Hubalek M, Pristauz G, Bauernhofer T, Eidtmann H, Eiermann W, Steger G, Kwasny W, Dubsky P, Hochreiner G, Forsthuber EP, Fesl C, Greil R; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria.

Lancet Oncol. 2011 Jul;12(7):631-41. doi: 10.1016/S1470-2045(11)70122-X. Epub 2011 Jun 5.

PMID:
21641868
32.

Sentinel node biopsy after primary chemotherapy in breast cancer: a note of caution from results of ABCSG-14.

Tausch C, Steger GG, Haid A, Jakesz R, Fridrik MA, Reitsamer R, Pöstlberger S, Lang A, Gnant M, Greil R.

Breast J. 2011 May-Jun;17(3):230-8. doi: 10.1111/j.1524-4741.2011.01073.x. Epub 2011 Mar 31.

PMID:
21450019
33.

Oncologic safety of breast conserving surgery after tumour downsizing by neoadjuvant therapy: a retrospective single centre cohort study.

Fitzal F, Riedl O, Mittlböck M, Dubsky P, Bartsch R, Steger G, Jakesz R, Gnant M.

Breast Cancer Res Treat. 2011 May;127(1):121-8. doi: 10.1007/s10549-010-1164-9. Epub 2010 Sep 17.

PMID:
20848185
34.

NeoGemOx: Gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer.

Sahora K, Kuehrer I, Eisenhut A, Akan B, Koellblinger C, Goetzinger P, Teleky B, Jakesz R, Peck-Radosavljevic M, Ba'ssalamah A, Zielinski C, Gnant M.

Surgery. 2011 Mar;149(3):311-20. doi: 10.1016/j.surg.2010.07.048. Epub 2010 Sep 6.

PMID:
20817204
35.

Osteooncology - Specific Aspects in Breast Cancer Patients.

Jakesz R.

Breast Care (Basel). 2010;5(5):288-289. Epub 2010 Oct 26. No abstract available.

36.

Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen.

Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, Buyse M, Baum M, Buzdar A, Colleoni M, Coombes C, Snowdon C, Gnant M, Jakesz R, Kaufmann M, Boccardo F, Godwin J, Davies C, Peto R.

J Clin Oncol. 2010 Jan 20;28(3):509-18. doi: 10.1200/JCO.2009.23.1274. Epub 2009 Nov 30.

PMID:
19949017
37.

HER2/neu expression correlates with vascular endothelial growth factor-C and lymphangiogenesis in lymph node-positive breast cancer.

Schoppmann SF, Tamandl D, Roberts L, Jomrich G, Schoppmann A, Zwrtek R, Dubsky P, Gnant M, Jakesz R, Birner P.

Ann Oncol. 2010 May;21(5):955-60. doi: 10.1093/annonc/mdp532. Epub 2009 Nov 25.

PMID:
19940005
38.

Adjuvant bisphosphonates in endocrine-responsive breast cancer: what is their place in therapy?

Gnant M, Blaha P, Dubsky P, Exner R, Fitzal F, Sporn E, Panhofer P, Borgo AD, Bigenzahn S, Steger G, Jakesz R.

Ther Adv Med Oncol. 2009 Nov;1(3):123-36. doi: 10.1177/1758834009344594.

39.

ONCOPOOL - a European database for 16,944 cases of breast cancer.

Blamey RW, Hornmark-Stenstam B, Ball G, Blichert-Toft M, Cataliotti L, Fourquet A, Gee J, Holli K, Jakesz R, Kerin M, Mansel R, Nicholson R, Pienkowski T, Pinder S, Sundquist M, van de Vijver M, Ellis I.

Eur J Cancer. 2010 Jan;46(1):56-71. doi: 10.1016/j.ejca.2009.09.009. Erratum in: Eur J Cancer. 2010 Jun;46(9):1762.

PMID:
19811907
40.

The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial.

de Azambuja E, McCaskill-Stevens W, Francis P, Quinaux E, Crown JP, Vicente M, Giuliani R, Nordenskjöld B, Gutiérez J, Andersson M, Vila MM, Jakesz R, Demol J, Dewar J, Santoro A, Lluch A, Olsen S, Gelber RD, Di Leo A, Piccart-Gebhart M.

Breast Cancer Res Treat. 2010 Jan;119(1):145-53. doi: 10.1007/s10549-009-0512-0.

PMID:
19731015
41.

The value of protecting the longitudinal staple line with invaginating sutures during esophageal reconstruction by gastric tube pull-up.

Silberhumer GR, Györi G, Burghuber C, Neumayer C, Riegler M, Jakesz R, Prager G, Schoppmann SF, Zacherl J.

Dig Surg. 2009;26(4):337-41. doi: 10.1159/000235825. Epub 2009 Aug 29.

PMID:
19729925
42.

Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy.

Filipits M, Rudas M, Heinzl H, Jakesz R, Kubista E, Lax S, Schippinger W, Dietze O, Greil R, Stiglbauer W, Kwasny W, Nader A, Stierer M, Gnant MF; Austrian Breast and Colorectal Cancer Study Group.

Clin Cancer Res. 2009 Sep 15;15(18):5888-94. doi: 10.1158/1078-0432.CCR-09-0728. Epub 2009 Sep 1.

43.

Breast cancer chemoprevention - a vision not yet realized.

Blaha P, Dubsky P, Fitzal F, Bachleitner-Hofmann T, Jakesz R, Gnant M, Steger G.

Eur J Cancer Care (Engl). 2009 Sep;18(5):438-46. doi: 10.1111/j.1365-2354.2008.00951.x. Epub 2009 Jul 20. Review.

PMID:
19686352
44.

Lymph node ratio after curative surgery for intrahepatic cholangiocarcinoma.

Tamandl D, Kaczirek K, Gruenberger B, Koelblinger C, Maresch J, Jakesz R, Gruenberger T.

Br J Surg. 2009 Aug;96(8):919-25. doi: 10.1002/bjs.6654.

PMID:
19591163
45.

Maintaining bone density in patients undergoing treatment for breast cancer: is there an adjuvant benefit?

Gnant M, Dubsky P, Fitzal F, Blaha P, Schoppmann S, Steger G, Marth C, Samonigg H, Hüttner K, Fohler H, Ruecklinger E, Jakesz R, Greil R; Austrian Breast and Colorectal Cancer Study Group.

Clin Breast Cancer. 2009 Jun;9 Suppl 1:S18-27. doi: 10.3816/CBC.2009.s.002. Review.

PMID:
19561003
46.

New epidemiological aspects of patients with severe hyperhidrosis presenting for sympathetic surgery.

Karimian-Teherani D, Panhofer P, Ringhofer C, Jakesz R, Prager M, Zacherl J, Bischof G, Neumayer C.

J Eur Acad Dermatol Venereol. 2009 Jun;23(6):651-5. doi: 10.1111/j.1468-3083.2009.03131.x. Epub 2009 Feb 24.

PMID:
19250333
47.

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rücklinger E, Greil R; ABCSG-12 Trial Investigators, Marth C.

N Engl J Med. 2009 Feb 12;360(7):679-91. doi: 10.1056/NEJMoa0806285. Erratum in: N Engl J Med. 2009 May 28;360(22):2379.

48.

Is Endocrine Therapy Really Pleasant? Considerations about the Long-Term Use of Antihormonal Therapy and Its Benefit/Side Effect Ratio.

Blaha P, Exner R, Borgo AD, Bigenzahn S, Panhofer P, Riedl O, Schoppmann S, Bachleitner-Hofmann T, Sporn E, Pluschnig U, Fitzal F, Steger G, Jakesz R, Dubsky P, Gnant M.

Breast Care (Basel). 2009;4(3):155-161. Epub 2009 Jun 23.

49.

Recent developments in breast-conserving surgery for breast cancer patients.

Fitzal F, Riedl O, Jakesz R.

Langenbecks Arch Surg. 2009 Jul;394(4):591-609. doi: 10.1007/s00423-008-0412-5. Epub 2008 Sep 10. Review.

PMID:
18781322
50.

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.

Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kässmann H, Piswanger-Sölkner JC, Seifert M, Ploner F, Menzel C, Dubsky P, Fitzal F, Bjelic-Radisic V, Steger G, Greil R, Marth C, Kubista E, Samonigg H, Wohlmuth P, Mittlböck M, Jakesz R; Austrian Breast and Colorectal Cancer Study Group (ABCSG).

Lancet Oncol. 2008 Sep;9(9):840-9. doi: 10.1016/S1470-2045(08)70204-3. Epub 2008 Aug 19.

PMID:
18718815

Supplemental Content

Loading ...
Support Center